Innovative Payment

NTRK1/2/3 CDx

NTRK1/2/3 CDx is the first NGS-based companion diagnostic product in pan-solid tumor , which comprehensively covers 18–20 million patients with solid tumors in China.
It will be used as a companion diagnostic to identify patients with NTRK1/2/3 fusions solid tumors who may be appropriate for treatment with Bayer's larotrectinib.
NTRK1/2/3 CDx developed by OrigiMed in cooperation with Bayer granted the Special Review Procedure for Innovative Medical Devices by the National Medical Products Administration (NMPA) of China.
NTRK1/2/3 CDx has completed EU CE certification and obtained the registration license issued by CIBG.

NTRK clinic is the first pan-cancer online clinic specifically for NTRK gene fusion. At NTRK clinic, over 500 NTRK-positive cancer patients have experienced full-course management services from diagnostic treatment to precision medicine.
NTRK clinic provides full-circle patient management including diagnosis, treatment, clinical trial and patient follow-up, bringing more survival benefits to Chinese NTRK-positive patients.

OrigiMed work with both Chinese healthcare system(CHS) and commercial insurance partners covering more than 40 cities across China.
OrigiMed partnered with Ping An Health Insurance, Roche on innovative payment program aiming to help Chinese NTRK-postivie patients reducing their medical cost and achieving longer survival goal.